GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Clearmind Medicine CMND · USD

Health Care · US listing · 🇺🇸 United States

Compare

5.50

-1.43%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

−$3.9m

FY2016FY2025

Free cash flow

−$4.7m

FY2016FY2025

Shareholders' equity

$1.2m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Gross profit−$49,364−$35,836−$40,299−$83,934−$1,773—————
Research and development$2.0m$962,600$1.1m$3.1m$445,859—————
Operating income−$5.7m−$4.0m−$4.4m−$6.3m−$2.5m−$163,649−$73,876−$178,606−$6,529−$16,992
Net income−$3.9m−$3.7m−$6.0m−$7.0m−$2.6m−$163,649−$73,876−$136,504−$6,529−$16,992
Diluted earnings per share-2.67-3.46-67.95-633.34-246.67-30.88-23.83-44.03-0.21-0.00

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$6.1m$7.1m$4.2m$787,088$2.9m$270,017$95,061$131,963$70,623$3,017
Cash and short-term investments$5.6m$6.7m$3.9m$307,179$2.6m$173,728$367$39,413$56,037—
Total liabilities$4.9m$4.1m$3.5m$1.8m$202,223$7,038$23,750$4,087$35,986$35,090
Debt$1.8m$51,906—$36,562—————$21,797
Shareholders' equity$1.2m$3.0m$690,097−$1.1m$2.7m$262,979$71,310$127,876$34,638−$32,073
Shares outstanding1m1m0m0m0m0m0m0m0m9m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$4.7m−$4.7m−$4.4m−$3.5m−$1.5m−$139,287−$33,577−$56,472−$8,929−$10,786
Capital spending———−$5,298−$118,854−$5,267−$5,329−$70,155−$18,422—
Free cash flow−$4.7m−$4.7m−$4.4m−$3.6m−$1.6m−$144,554−$38,905−$126,626−$27,351−$10,786

Latest quarters

By quarter end

Jul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024
Gross profit−$14,218−$13,901−$13,318−$12,836−$12,522−$11,978−$12,031−$8,077
Operating income−$2.2m−$1.6m−$3.7m−$1.5m−$1.4m−$1.3m−$1.5m−$1.1m
Net income−$907,291−$2.0m−$3.9m−$687,777−$1.3m−$784,513−$1.1m−$620,818
Diluted earnings per share-0.57-1.29-2.43-0.48-0.91-0.54-0.74-0.58
Cash from operations−$1.0m−$1.0m−$2.0m−$1.0m−$1.0m−$1.0m−$1.0m−$1.0m
Total assets$16.9m$14.5m$11.1m$8.5m$5.5m$7.2m$9.7m$7.1m
Cash and short-term investments$15.9m$13.6m$10.3m$5.6m$4.8m$6.4m$8.7m$6.7m
Debt$1.7m$41,241$7,977$2.5m$39,184$49,712$57,616$35,872
Shareholders' equity$13.0m$11.5m$8.2m$1.7m$1.5m$3.2m$4.2m$3.0m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-3.6%103.2%67.4%
Net income-17.9%88.1%61.0%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings-21.4-318.8-18.8-11.8

Share price return

Finished calendar years

2025202420232022
Return-91%-27%-87%-34%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 8-to-1 reverse split · 5 Oct 2026
  • 10-to-1 reverse split · 21 May 2026
  • 40-to-1 reverse split · 15 Dec 2025
  • 30-to-1 reverse split · 28 Nov 2023
  • 30-to-1 reverse split · 30 Sept 2022

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.